Crescita Therapeutics™ Announces the Appointment of Serge Verreault as President & CEO
Apr 03, 2018, 07:30 ET
MISSISSAUGA, ON, April 3, 2018 /CNW/ - Crescita Therapeutics Inc. (TSX: CTX) ("Crescita" or the "Company"), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms, today announced the appointment of Mr. Serge Verreault, Crescita's current President, as President and CEO of the Company effective April 2, 2018. Mr. Dan Chicoine will continue as Crescita's Executive Chairman and to serve on the Company's board of directors.
"We are pleased that Serge will assume this new leadership role at Crescita," said Anthony Dobranowski, Crescita's Lead Director. "As President of Crescita, Serge has proven himself to be a capable leader and motivator with the knowledge and experience to execute our growth strategy of building a profitable and successful North American skincare company serving both the non-prescription and prescription markets."
"I am very excited to assume this new position. I believe Crescita is well positioned to become a leader in skin care as we have the products and technologies to grow the business into a leading dermatological company," said Serge Verreault, President & CEO.
Prior to joining Crescita in April 2017, Mr. Verreault worked at Valeant Canada for fourteen years in a variety of positions. Most recently, Mr. Verreault was the Executive Director of Business Development and a member of the Operating Committee. During his tenure in this role, he also served as the General Manager of Laboratoire Dr Renaud™. Laboratoire Dr Renaud is one of the product lines that Crescita acquired as part of the INTEGA Skin Sciences Inc. acquisition in September 2016.
Mr. Verreault has executed more than thirty licensing and acquisition deals acting in every step of the business development process, from lead generation to integration, and participated in some of the global deals for the Canadian operation at Valeant. Prior to joining Valeant, Mr. Verreault worked at Medicago Inc. and Dismed Inc. Mr. Verreault holds a B.A. and an M.B.A. in International Marketing from Laval University and a Diploma in Nursing.
About Crescita Therapeutics Inc.
Crescita (TSX: CTX) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin. For additional information, please visit www.crescitatherapeutics.com.
Forward-Looking Statements
This Press Release contains "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company's current beliefs, expectations and assumptions, the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. Crescita's actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, readers should not rely on any of these forward-looking statements. Important factors that could cause Crescita's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, the risk factors included in Crescita's most recent Annual Information Form dated March 28, 2018 under the heading "Risks Factors", and as described from time to time in the reports and disclosure documents filed by Crescita with Canadian securities regulatory agencies and commissions. These and other factors should be considered carefully, and readers should not place undue reliance on Crescita's forward-looking statements. As a result of the foregoing and other factors, no assurance can be given as to any such future results, levels of activity or achievements and none of Crescita or any other person assumes responsibility for the accuracy and completeness of these forward-looking statements. Any forward-looking statement made by the Company in this Press Release is based only on information currently available to it and speaks only as of the date on which it is made. Except as required by applicable securities laws, Crescita undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
SOURCE Crescita Therapeutics Inc.
For further information: Investor Relations, Email: ir@crescitatx.com
Share this article